Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi Ends Insulin Deal With MannKind

by Ann M. Thayer
January 11, 2016 | A version of this story appeared in Volume 94, Issue 2

Sanofi has ended its license and collaboration agreement with MannKind after disappointing sales of the inhaled insulin product Afrezza. In August 2014, MannKind and Sanofi signed a $925 million deal to develop and commercialize Afrezza. The companies launched Afrezza in February 2015, but sales totaled only $5 million for the first nine months of 2015. MannKind had spent more than a decade and $2.6 billion to develop an inhaled insulin while many larger firms halted their attempts. The product will be transitioned back to MannKind, which is looking to find a new partner, marketing strategy, and pricing approach.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.